Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our positive fourth quarter results reflect the strong patient demand for Inspire therapy and an increased number of prior authorization submissions, trends that we expect to continue in 2024 |
| The team's commitment to patients remains unmatched and is the most important element to our success |
| In conclusion, our strong performance and business momentum provide us with confidence in our outlook heading into 2024 |
| As always, I'm grateful to the growing team of dedicated Inspire employees for their enthusiasm, hard work, and continued motivation to achieve successful and consistent patient outcomes |
| But we are excited for 2024 with the guidance that we set forth and we're going to strive to increase utilization |
| We expect our improved operating leverage will continue into 2024 and to be profitable for the second half of 2024 |
| Furthermore, the fourth quarter of 2023 was exceptionally strong based on the recovery from the third quarter |
| Looking ahead, we expect to generate positive cash flow for the full year 2024 |
| So, pretty excited about France is a very significant opportunity for sleep apnea and for the Inspire technology |
| And so the Inspire IV system is a very strong system, provides very strong outcomes |
| In fact, the clinical evidence of our product today is superior to the evidence that we were approved on with the STAR trial |
| The year-over-year increase was driven by improved manufacturing yields and higher volumes |
| And it's the ENT having gained additional experience and having a strong team |
| We remain excited about future prospects and are confident that we have the appropriate strategy in place to drive long-term stakeholder value |
| And we know the Netherlands and Belgium are strong because they had derogation earlier in 20023 in the fourth quarter that allowed us to start shipping product there |
| We are excited to report our first quarter with operating income and a very strong finish to the year |
| We're excited |
| And we did demonstrate strengthening of our operating leverage in the model |
| This office procedure will significantly improve the patient experience and should unlock physician capacity to perform additional Inspire procedures |
| Further, we have onboarded a third-party vendor to assist our market access team with the prior authorization process, which increases our capacity to meet a strong and growing patient demand |
| I mean we provide guidance on an annual basis, but we're excited about the leverage that we demonstrated in the fourth quarter and the confidence we have in our revenue number for 2024 |
| On the product development side, our pipeline remains robust |
| As far as Inspire V submission, team is doing a great job |
| The strong cash position allows us to remain focused on executing our growth strategy of increasing procedure volumes at existing centers while training and opening new implanting centers |
| So we had a very strong fourth quarter, and that's where we mentioned we might have some more pronounced seasonality |
| It takes less time to do the procedure, they gain confidence in the procedure, but it's essential that they have a strong partnership with sleep physicians to be able to manage the patients longitudinally |
| I think Germany is really coming back strong now that we're able to start shipping product after the relabeling effort |
| But net-net, it looks like a huge positive |
| Tim and Rick, congrats to the strong start -- strong end to the year and solid guidance that you put out earlier at JPMorgan |
| Positive announcement earlier in the year, Jan 1 |
| Statement |
|---|
| As Tim noted, this was due to the delay of the EU MDR approval that impeded our ability to ship silicon based leads in Europe during the fourth quarter |
| International revenue declined 16% to $3.1 million |
| Revenue outside the US was $3.1 million, which is a 16% decrease year-over-year |
| We had our challenges with getting derogation approval, primarily in Germany in 2023 |
| We have challenges getting enough ENT time to be in the operating room to do the procedures |
| Those patients who are untreated with moderate to severe sleep apnea have a significant challenge with quality of life, and they are motivated to receive therapy |
| We know that's going to be a little bit of a challenge for the drug, as long as the compliance and the weight loss is there to support that |
| Rick, for 1Q 2024 US revs to be down mid- to high teens Q-over-Q, I need to get 1Q 2024 year-over-year utilization down 2% to 3% year-over-year |
| That's where we're having trouble |
| Regarding the outside the U.S., we had mentioned before that we would -- we could see a $4 million headwind in the fourth quarter |
| If you're a low BMI, it's very difficult to have a significant AHI reduction |
| And that would be the first down year-over-year utilization since arguably the throes of COVID, and now you've got broader labels, you've got the pediatric opportunity in some of those facilities |
| We know the challenges with some of the technology out there today |
| We're going to lose some of that leverage with our more pronounced seasonality in Q1, but then we'll return to that |
| And we certainly don't have challenges with patient flow |
| We don't necessarily have challenges getting operating room time |
| And we know that we stimulate the hypoglossal nerve that moves the base of the tongue forward, that's very difficult for our patients to be able to get that level of reduction in AHI, but we want the patient to lose weight, have relaxation of the lateral wall |
| And related to that, you also talked about headwind outside of the U.S |
| And you can imagine that's a pretty uncomfortable forward movement therefore, it's pretty limited when you get to the more severe cases |
| But we don't see it being really disruptive in the year |
Please consider a small donation if you think this website provides you with relevant information